Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
AML
•
Hematology
How do you approach c-KIT mutated, core binding factor (CBF) AML?
How does the mutation impact prognosis and your decision on transplantation?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How do you manage ocular hemorrhages while on acalabrutinib for CLL?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?